Suppr超能文献

美国有资格接受司美格鲁肽治疗的超重和肥胖成年人在经济障碍方面的种族和民族差异。

Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States.

机构信息

Center for Outcomes Research and Evaluation Yale New Haven Hospital New Haven CT.

Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine New Haven CT.

出版信息

J Am Heart Assoc. 2022 Oct 4;11(19):e025545. doi: 10.1161/JAHA.121.025545. Epub 2022 Sep 29.

Abstract

Background Semaglutide holds the promise for weight loss and risk reduction. Less is known about racial and ethnic disparities in financial barriers among the semaglutide-eligible population. Methods and Results We conducted a cross-sectional analysis of adults aged 18 years or older using data from the National Health and Nutrition Examination Survey 2015 to 2020. We analyzed adults eligible for semaglutide based on Food and Drug Administration labeling and assessed financial barriers and social determinants of health among the eligible population overall and by race and ethnicity. A total of 13 711 adults were included in the final analysis. In 2015 to 2020, 51.1% (48.3%-53.2%) of US adults (≈43.3 million) met the Food and Drug Administration eligibility criteria for semaglutide. The percentage of adults eligible for semaglutide was highest among Black adults (56.6% [54.2%-59.1%]), followed by Hispanic adults (55.0% [52.8%-57.3%]). Among adults eligible for semaglutide, 11.9% (10.1%-13.6%) were uninsured, 13.3% (12.1%-14.5%) lacked a usual source of care, 33.6% (30.2%-36.9%) had low family income, and 38.9% (36.5%-41.3%) lacked higher education. Compared with White individuals, significantly larger proportions of Black and Hispanic individuals were uninsured, lacked a usual source of care, had low family income, or lacked higher education (<0.001 for all). Conclusions Many Americans who were eligible for semaglutide were likely to be unable to afford the medication. Among the eligible population, a larger proportion of Black and Hispanic adults had financial barriers than other subgroups.

摘要

背景

司美格鲁肽具有减肥和降低风险的作用。关于司美格鲁肽合格人群在经济障碍方面的种族和民族差异,了解较少。

方法和结果

我们使用 2015 年至 2020 年全国健康和营养调查的数据,对年龄在 18 岁或以上的成年人进行了横断面分析。我们根据食品和药物管理局的标签分析了有资格使用司美格鲁肽的成年人,并评估了合格人群的经济障碍和健康的社会决定因素,以及按种族和民族进行的评估。共有 13711 名成年人纳入最终分析。2015 年至 2020 年,51.1%(48.3%-53.2%)的美国成年人(≈4330 万)符合司美格鲁肽的食品和药物管理局资格标准。黑种成年人(56.6%[54.2%-59.1%])有资格使用司美格鲁肽的比例最高,其次是西班牙裔成年人(55.0%[52.8%-57.3%])。在有资格使用司美格鲁肽的成年人中,11.9%(10.1%-13.6%)没有保险,13.3%(12.1%-14.5%)没有常规医疗来源,33.6%(30.2%-36.9%)家庭收入低,38.9%(36.5%-41.3%)没有接受过高等教育。与白人相比,黑人和西班牙裔的成年人没有保险、没有常规医疗来源、家庭收入低或没有接受过高等教育的比例显著更大(<0.001)。

结论

许多有资格使用司美格鲁肽的美国人可能负担不起这种药物。在合格人群中,黑人和西班牙裔成年人的经济障碍比例高于其他亚组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95ce/9673703/1177c4cf1360/JAH3-11-e025545-g002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验